Table 1.
LDL-C pre-apheresis, post-apheresis and inter-apheresis values at baseline, before LDL-C apheresis period and during apheresis period, with different doses of lomitapide in Patient 1
| Timing of lipid measurement | LDL-C, mg/dL | AST/ALT, UI/L | |||
| Preapheresis | Postapheresis | Interapheresis | Time averaged* | ||
| Baseline | 747 | – | – | – | – |
| Before commencement of apheresis | 198 | – | – | – | – |
| Apheresis | 168 | 56 | 128 | 138 | 42/39 |
| Apheresis+lomitapide 5 mg/day | 86 | 39 | 69 | 73 | 37/45 |
| Apheresis+lomitapide 10 mg/day | 36 | 19 | 25 | 31 | 31/37 |
| Lomitapide monotherapy 10 mg/day | 40 | – | – | – | – |
| Apheresis procedures, n | SCA events/year, pre-apheresis | SCA events/first year, on apheresis | SCA and other events/year on apheresis and/or lomitapide | Xanthomas | |
| 154 | 1 | 0 | 0 | ++ → 0 | |
*Time averaged LDL-C is calculated according to the formula by Kroon et al (C(AVG)=C(MIN)+0.73(C(MAX)-C(MIN)), where C(MAX) and C(MIN) are the immediate pre- and post-treatment levels.11
+, xanthoma severity; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDL-C, low-density lipoprotein cholesterol; SCA, sudden cardiac arrest.